Literature DB >> 7723367

Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma.

K Yamaguchi1, B I Carr, M A Nalesnik.   

Abstract

Single and double immunohistochemical staining for transforming growth factor (TGF)-alpha and epidermal growth factor-receptor (EGF-R) was done in order to identify the localization of TGF-alpha and EGF-R in human hepatocellular carcinoma (HCC). Single immunohistochemical staining for TGF-alpha showed immunoreactivity in the cytoplasm of hepatoma cells in 22 of 30 cases of HCC. The localization of TGF-alpha was heterogeneous from HCC cells to HCC cells. In the surrounding regenerative nodules, the hepatocytes were mildly to moderately positive for TGF-alpha. The proliferating bile ductules and peripheral nerves were also immunopositive for TGF-alpha. Single immunohistochemical staining for EGF-R demonstrated a linear localization of EGF-R along the cell membrane of the HCC cells in 21 of the 30 cases of HCC. In the regenerative nodules, the hepatocytes also showed linear staining along the cell membrane. Double staining for TGF-alpha and EGF-R in 12 cases of HCC showed a concurrent localization of TGF-alpha and EGF-R in some hepatoma cells and isolated localization of the two substances of other HCC cells. These combinations either abruptly moved around or intermingled with each other. These immunohistochemical results thus support the theory of an autocrine, paracrine, and endocrine mechanism of TGF-alpha and EGF-R on the proliferation of human hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7723367     DOI: 10.1002/jso.2930580409

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  10 in total

1.  Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer.

Authors:  Philip A Philip; Michelle R Mahoney; Kyle D Holen; Donald W Northfelt; Henry C Pitot; Joel Picus; Patrick J Flynn; Charles Erlichman
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

2.  Roles of EGFR-Stat3 signal pathway in carcinogenesis of experimental hepatoma in rats.

Authors:  Xiao Tang Yu; Shi Neng Zhu; Zu De Xu; Xi Qi Hu; Teng Fang Zhu; Jie Qing Chen; Shi Lun Lu
Journal:  J Cancer Res Clin Oncol       Date:  2006-10-10       Impact factor: 4.553

3.  New pharmacological developments in the treatment of hepatocellular cancer.

Authors:  Niraj J Gusani; Yixing Jiang; Eric T Kimchi; Kevin F Staveley-O'Carroll; Hua Cheng; Jaffer A Ajani
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 4.  Experimental models of hepatocellular carcinoma.

Authors:  Philippa Newell; Augusto Villanueva; Scott L Friedman; Kazuhiko Koike; Josep M Llovet
Journal:  J Hepatol       Date:  2008-01-30       Impact factor: 25.083

Review 5.  Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy.

Authors:  Khanh Nguyen; Kerri Jack; Weijing Sun
Journal:  Diseases       Date:  2015-12-25

6.  Smad2 and Smad3 Regulate Chondrocyte Proliferation and Differentiation in the Growth Plate.

Authors:  Weiguang Wang; Buer Song; Teni Anbarchian; Anna Shirazyan; Joshua E Sadik; Karen M Lyons
Journal:  PLoS Genet       Date:  2016-10-14       Impact factor: 5.917

7.  Inherent growth advantage of (pre)malignant hepatocytes associated with nuclear translocation of pro-transforming growth factor alpha.

Authors:  E Schausberger; K Hufnagl; W Parzefall; C Gerner; D Kandioler-Eckersberger; F Wrba; M Klimpfinger; R Schulte-Hermann; B Grasl-Kraupp
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

Review 8.  Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.

Authors:  So Young Yoo; Narayanasamy Badrinath; Hyun Young Woo; Jeong Heo
Journal:  Mediators Inflamm       Date:  2017-04-20       Impact factor: 4.711

9.  The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.

Authors:  Silvia Ribback; Verena Sailer; Enrico Böhning; Julia Günther; Jaqueline Merz; Frauke Steinmüller; Kirsten Utpatel; Antonio Cigliano; Kristin Peters; Maria G Pilo; Matthias Evert; Diego F Calvisi; Frank Dombrowski
Journal:  Int J Mol Sci       Date:  2016-09-23       Impact factor: 5.923

10.  Bioinformatic Analysis of Hepatocellular Carcinoma Cell Lines to the Efficacy of Nimotuzumab.

Authors:  Yu Wang; Meng Zhang; Yixin Gong; Qiyan Wu; Lijun Zhang; Shunchang Jiao
Journal:  Int J Gen Med       Date:  2021-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.